Eltrombopag Olamine

CAS 496775-62-3

General Information

Eltrombopag olamine a type of thrombopoietin receptor agonist and is used to treat thrombocytopenia (a lower-than-normal number of platelets in the blood) in patients with chronic immune thrombocytopenic purpura (a condition in which platelets are destroyed by the immune system).

Eltrombopag was discovered as a result of research collaboration between GlaxoSmithKline and Ligand Pharmaceuticals.

Eltrombopag olamine is used in patients whose condition did not improve with corticosteroids, immunoglobulins, or surgery to remove the spleen. Eltrombopag olamine is also used to treat severe aplastic anemia.

It is also being studied in the treatment of other conditions and types of cancer. Eltrombopag olamine causes more platelets to be made in the bone marrow.

Teva api is offering the eltrombopag API as an olamine salt for easier biostudy. Our fully back integrated process ensures a good quality API with a low content of genotoxic impurities. At Teva api eltrombopag olamine is produced in Europe.

We have successfully developed all analytical methods, including those for genotoxic impurities.

Eltrombopag olamine GMP samples are available for your regulatory needs.

About the API

Molecular Weight 564.6 g/mol
Therapeutic category Hematology
Available formulations Oral Solid
Regulations EU DMF Flag EU DMF